Clinical Trial Update: A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Alectinib with Crizotinib and assessing pharmacokinetics in Asian participants with treatment-naive ALK-positive advanced non-small cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alecensa (alectinib)
• Xalkori (crizotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2019-07-11